Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

Zacks Investment Research • Feb 10, 2026

CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up

CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.

Zacks Investment Research • Jan 29, 2026

CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript

CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript

Seeking Alpha • Jan 29, 2026

CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to dilute.

Business Wire • Jan 28, 2026

Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Jan 29, 2026

CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

CONMED Corporation Announces Chief Financial Officer Transition

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. “On behalf of our Board and leadership team, I.

Business Wire • Jan 8, 2026

CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed.

Business Wire • Jan 5, 2026

CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, January 12, 2026 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.conmed.com and.

Business Wire • Jan 5, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.

Zacks Investment Research • Dec 31, 2025